Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 18/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.58 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.58 |
| ▸ | F13A1 | P00488 | 2/20 | 0.53 |
| ▸ | TGM1 | P22735 | 2/20 | 0.53 |
| ▸ | TGM6 | O95932 | 1/20 | 0.53 |
| ▸ | KLK7 | P49862 | 1/20 | 0.51 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21219350 | 1.00 | TGM2 (0.59) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL26120906 | 0.94 | TGM2 (0.58) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL26120901 | 0.94 | TGM2 (0.58) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL20975607 | 0.90 | ITGB3 (0.52) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL21219330 | 0.88 | TGM2 (0.49) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL21219331 | 0.88 | TGM2 (0.49) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL20873003 | 0.88 | DPP8 (0.58) | TGM2ITGB3ITGA2BKLK7KLK5 | |
| SCHEMBL28270832 | 0.88 | ITGB3 (0.52) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL21009799 | 0.85 | ITGB3 (0.62) | TGM2ITGB3ITGA2BF13A1TGM1 | |
| SCHEMBL19707914 | 0.85 | ITGB3 (0.62) | TGM2ITGB3ITGA2BF13A1TGM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3521301-B1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN BIOTECH BIOPHARMACEUTICAL CO LTD (CN) | 2024-03-06 | — | — | EP | disclosed |
| US-11084847-B2 | Polyamide compound and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-08-10 | — | — | US | disclosed |
| US-20200109166-A1 | POLYAMIDE COMPOUND AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-04-09 | — | — | US | disclosed |
| EP-3521301-A1 | POLYAMIDE COMPOUND AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2019-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11084847-B2 | Polyamide compound and use thereof | OPRK1, OPRM1, OPRD1 | TGM2 2129/4885ITGB3 2660/4885ITGA2B 2954/4885 |
| US-20200109166-A1 | POLYAMIDE COMPOUND AND USE THEREOF | OPRK1, OPRM1, OPRD1 | TGM2 2129/4885ITGB3 2660/4885ITGA2B 2954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.